Krystal Biotech, Inc. (KRYS) Tops Q2 EPS by 7c, Beats on Revenue

Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q2 EPS of $1.29, $0.07 better than the analyst estimate of $1.22. Revenue for the quarter came in at $96.04 million versus the consensus estimate of $92.24 million.

For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.

You May Also Be Interested In

• Vail Resorts (MTN) 2200 contracts October 145 puts trade into quarter results
• Lee Enterprises acquires South Dakota and Montana papers from USA TODAY Co.
• Active options: GOOGL ORCL SOFI AMC AVGO NFLX IREN MSTR PLTR GME